Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Other Non Operating Income (2016 - 2025)

Fate Therapeutics' Other Non Operating Income history spans 14 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 127.57% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $4.9 million, up 164.33%, while the annual FY2025 figure was $11.4 million, 92.81% up from the prior year.
  • Other Non Operating Income reached $2.3 million in Q4 2025 per FATE's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $9.8 million in Q2 2023 to a low of -$8.5 million in Q4 2024.
  • Average Other Non Operating Income over 5 years is $2.1 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: plummeted 4726.09% in 2024, then skyrocketed 806.93% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $4.8 million in 2021, then surged by 66.34% to $8.1 million in 2022, then tumbled by 97.72% to $184000.0 in 2023, then tumbled by 4726.09% to -$8.5 million in 2024, then skyrocketed by 127.57% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Other Non Operating Income are $2.3 million (Q4 2025), $2.5 million (Q3 2025), and $50000.0 (Q2 2025).